BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,144,985 | +31.0% | 43,420 | -14.6% | 0.01% | +50.0% |
| Q2 2023 | $874,104 | +106238.7% | 50,820 | +2.6% | 0.01% | 0.0% |
| Q1 2023 | $822 | +122.8% | 49,550 | +2.3% | 0.01% | +100.0% |
| Q4 2022 | $369 | -99.9% | 48,420 | -4.5% | 0.00% | -25.0% |
| Q3 2022 | $505,000 | +6212.5% | 50,712 | +5656.2% | 0.00% | – |
| Q2 2022 | $8,000 | -98.5% | 881 | -98.3% | 0.00% | -100.0% |
| Q1 2022 | $525,000 | +2.3% | 51,681 | -0.6% | 0.00% | 0.0% |
| Q4 2021 | $513,000 | +44.9% | 52,011 | +588.2% | 0.00% | +100.0% |
| Q3 2021 | $354,000 | -21.7% | 7,558 | +2.0% | 0.00% | -33.3% |
| Q2 2021 | $452,000 | +18.0% | 7,411 | +19.3% | 0.00% | +50.0% |
| Q1 2021 | $383,000 | -7.3% | 6,211 | +6.9% | 0.00% | -33.3% |
| Q4 2020 | $413,000 | +293.3% | 5,811 | +106.8% | 0.00% | +200.0% |
| Q3 2020 | $105,000 | +483.3% | 2,810 | +410.9% | 0.00% | – |
| Q2 2020 | $18,000 | +12.5% | 550 | 0.0% | 0.00% | – |
| Q1 2020 | $16,000 | – | 550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |